Rakuten Medical and LOTTE Biologics Forge Strategic Manufacturing Pact
Rakuten Medical, Inc. and LOTTE Biologics have recently announced a significant contract manufacturing agreement aimed at bolstering the production capabilities of Rakuten Medical's groundbreaking oncology therapy. This collaboration emerged during a prestigious healthcare conference in San Francisco, a gathering that highlighted innovations in healthcare and biopharmaceuticals.
Latest Developments in Biopharmaceutical Production
Under the newly established agreement, LOTTE Biologics will deliver advanced manufacturing services tailored specifically for monoclonal antibody intermediates and their conjugates. This support is essential for Rakuten Medical's ambitious global clinical development plans and the future commercialization of its therapies.
The Alluminox® Platform
Rakuten Medical has developed a proprietary photoimmunotherapy technology known as the Alluminox® platform, which is designed to target solid tumors effectively. This technology integrates cell-targeting agents like antibodies with light-activatable compounds, allowing for the precise and direct destruction of tumor cells when exposed to light.
Global Expansion of Oncology Therapy
In Japan, this innovative therapy has received approval for treating recurrent head and neck cancer. The application of this therapy has grown, bolstered by consistent adoption and a steady increase in the number of treatments each year. Currently, a global Phase 3 clinical trial is in progress across multiple regions, including the United States, Taiwan, and Japan, with plans to expand treatments to additional regions shortly.
Future Clinical Trials
In an exciting development, Rakuten Medical intends to initiate a Phase 1 clinical trial targeting other solid tumors within Japan this year. The growing interest and demand for Rakuten Medical's bioconjugates reflect an encouraging trend in cancer treatment approaches.
LOTTE Biologics' Role in the Partnership
LOTTE Biologics has been enhancing its capabilities as a global contract development and manufacturing organization (CDMO), focusing on monoclonal and multispecific antibodies, antibody-drug conjugates (ADCs), and advanced bioconjugation services. They will utilize their specialized ADC manufacturing facility located within the Syracuse Bio Campus, New York, to support Rakuten Medical's projects.
This facility is specifically equipped to handle ADC production and boasts cutting-edge bioconjugation technologies, ensuring high-quality manufacturing services compliant with global regulatory standards, while maintaining stable supplies for customers around the world.
About LOTTE Biologics
LOTTE Biologics, founded in 2022 and headquartered in Seoul, South Korea, offers integrated biologics facilities in both the United States and South Korea. Through its Dual Hub Service model, the company enhances supply security, scalability in manufacturing, and upholds stringent quality standards.
They provide modular, phase-appropriate manufacturing solutions that support the entire process from preclinical phases to commercial production capabilities. LOTTE Biologics has proven adept at producing mammalian-cell-based biologics, including monoclonal antibodies and fusion proteins.
Infrastructure and Future Plans
At the Syracuse Bio Campus, LOTTE Biologics delivers GMP drug substance manufacturing, supported by over 62 global regulatory approvals. The site offers an impressive 40,000 liters of total capacity across multiple bioreactors of various sizes. Furthermore, the company is expanding into ADCs through strategic investments, creating an efficient, end-to-end production pathway for biologic drugs.
In South Korea, the company is actively constructing three advanced bio plants on the Songdo Bio Campus, with plans for the first facility to commence operations in the near future. These plants will be equipped with multiple large-scale bioreactors, significantly increasing their manufacturing capabilities.
About Rakuten Medical, Inc.
Rakuten Medical, Inc. is a leading global biotechnology firm specializing in the development and commercialization of its Alluminox® platform-based photoimmunotherapy. This technology has showcased the potential for rapid and targeted cancer cell destruction. As of now, Rakuten Medical's therapies are investigational outside Japan, but the company is dedicated to its mission of combating cancer worldwide.
With a presence in five key regions—including the United States, where its headquarters is located—Rakuten Medical aims to make its pioneering cancer treatments available to as many patients as possible.
Frequently Asked Questions
What is the partnership between Rakuten Medical and LOTTE Biologics about?
The partnership focuses on a contract manufacturing agreement to improve biopharmaceutical production capabilities for oncology therapies.
What is the Alluminox® platform?
The Alluminox® platform is Rakuten Medical's investigational photoimmunotherapy technology designed for targeted tumor cell destruction.
Where is LOTTE Biologics expanding its facilities?
LOTTE Biologics is expanding its capabilities in New York and constructing new bio plants in South Korea.
What types of drug substances will LOTTE Biologics manufacture?
LOTTE Biologics will produce monoclonal antibody intermediates and their conjugates for Rakuten Medical.
What is the significance of the recent clinical trials initiated by Rakuten Medical?
The trials aim to expand the therapeutic applications of photoimmunotherapy to other types of solid tumors beyond head and neck cancer.
